3 results about "Erlotinib" patented technology

The invention relates to the technical field of chemical synthesis of medicines, and particularly discloses a production and preparation method of an erlotinib intermediate. The method comprises the following steps: taking 3, 4-dihydroxy benzaldehyde as an initial raw material, sequentially carrying out etherification, oxidation and nitration reactions to prepare 2-nitro-4, 5-bis (2-methoxyethoxy) benzoic acid, finally dissolving the 2-nitro-4, 5-bis (2-methoxyethoxy) benzoic acid, formamide, formic acid and triethylamine in gamma-valerolactone to form two material flows, and carrying out heat treatment to obtain the 2-nitro-4, 5-bis (2-methoxyethoxy) benzoic acid. And carrying out continuous cyclization reaction in a fixed bed reactor filled with a specific composite catalyst, and carrying out post-treatment to obtain the target product 6, 7-bis (2-methoxyethoxy)-4-quinazolinone. According to the method, the raw materials are easy to obtain, the reaction efficiency and the product purity are remarkably improved by optimizing the synthesis route and the reaction conditions, and a novel efficient, environment-friendly and stable method is provided for large-scale production of the erlotinib key intermediate.

This invention, entitled "Combined Application and Product of BAM-15 and Erlotinib," belongs to the field of combined antitumor drug application technology. The technical problem it aims to solve is the low response and limited efficacy of existing erlotinib monotherapy to EGFR wild-type lung adenocarcinoma, and the lack of effective targeted intervention options in clinical practice. The key points of the technical solution are: combining BAM-15 and erlotinib for the interventional treatment of EGFR wild-type lung adenocarcinoma; the combination produces a significant synergistic effect, with tumor suppression superior to the additive effect of using either drug alone, without antagonistic effects, effectively enhancing the inhibitory effect on EGFR wild-type lung adenocarcinoma and enriching clinical treatment options for tumors.